Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.
Krasniqi E, Goeman F, Pulito C, Palcau AC, Ciuffreda L, Di Lisa FS, Filomeno L, Barba M, Pizzuti L, Cappuzzo F, Sanguineti G, Maugeri-Saccà M, Ciliberto G, Fanciulli M, Blandino G, Vici P. Krasniqi E, et al. Among authors: filomeno l. Int J Mol Sci. 2022 Nov 22;23(23):14534. doi: 10.3390/ijms232314534. Int J Mol Sci. 2022. PMID: 36498861 Free PMC article. Review.
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer.
Grassadonia A, De Luca A, Carletti E, Vici P, Di Lisa FS, Filomeno L, Cicero G, De Lellis L, Veschi S, Florio R, Brocco D, Alberti S, Cama A, Tinari N. Grassadonia A, et al. Among authors: filomeno l. Cancers (Basel). 2022 Sep 25;14(19):4670. doi: 10.3390/cancers14194670. Cancers (Basel). 2022. PMID: 36230592 Free PMC article. Review.
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study.
Krasniqi E, Di Lisa FS, Di Benedetto A, Barba M, Pizzuti L, Filomeno L, Ercolani C, Tinari N, Grassadonia A, Santini D, Minelli M, Montemurro F, Fabbri MA, Mazzotta M, Gamucci T, D'Auria G, Botti C, Pelle F, Cavicchi F, Cappelli S, Cappuzzo F, Sanguineti G, Tomao S, Botticelli A, Marchetti P, Maugeri-Saccà M, De Maria R, Ciliberto G, Sperati F, Vici P. Krasniqi E, et al. Among authors: filomeno l. Cancers (Basel). 2022 Oct 3;14(19):4835. doi: 10.3390/cancers14194835. Cancers (Basel). 2022. PMID: 36230758 Free PMC article.
Sexual dysfunctions in breast cancer patients: evidence in context.
Vizza R, Capomolla EM, Tosetto L, Corrado G, Bruno V, Chiofalo B, Di Lisa FS, Filomeno L, Pizzuti L, Krasniqi E, Sanguineti G, Villa A, Giannini A, Kayal R, Stranges V, Tomao S, Botti C, Tomao F, Barba M, Vizza E, Ciliberto G, Vici P. Vizza R, et al. Among authors: filomeno l. Sex Med Rev. 2023 Jun 27;11(3):179-195. doi: 10.1093/sxmrev/qead006. Sex Med Rev. 2023. PMID: 37076125 Review.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, Borella F, Foglietta J, Cariello A, Ferro A, Picardo E, Mitidieri M, Sini V, Stani S, Tonini G, Santini D, La Verde N, Gambaro AR, Grassadonia A, Tinari N, Garrone O, Sarobba G, Livi L, Meattini I, D'Auria G, Vergati M, Gamucci T, Pistelli M, Berardi R, Risi E, Giotta F, Lorusso V, Rinaldi L, Artale S, Cazzaniga ME, Zustovich F, Cappuzzo F, Landi L, Torrisi R, Scagnoli S, Botticelli A, Michelotti A, Fratini B, Saltarelli R, Paris I, Muratore M, Cassano A, Gianni L, Gaspari V, Veltri EM, Zoratto F, Fiorio E, Fabbri MA, Mazzotta M, Ruggeri EM, Pedersini R, Valerio MR, Filomeno L, Minelli M, Scavina P, Raffaele M, Astone A, De Vita R, Pozzi M, Riccardi F, Greco F, Moscetti L, Giordano M, Maugeri-Saccà M, Zennaro A, Botti C, Pelle F, Cappelli S, Cavicchi F, Vizza E, Sanguineti G, Tomao F, Cortesi E, Marchetti P, Tomao S, Speranza I, Sperduti I, Ciliberto G, Vici P. Di Lisa FS, et al. Among authors: filomeno l. Front Oncol. 2023 May 16;13:1152123. doi: 10.3389/fonc.2023.1152123. eCollection 2023. Front Oncol. 2023. PMID: 37260975 Free PMC article.
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Bon G, Krasniqi E, Porru M, D'Ambrosio L, Scalera S, Maugeri-Saccà M, Di Lisa FS, Filomeno L, Arcuri T, Botticelli A, Santini D, Fabbri MA, D'Auria G, Pulito C, Blandino G, Marchiò C, Barba M, Ciliberto G, Vici P, Pizzuti L. Bon G, et al. Among authors: filomeno l. Neoplasia. 2023 Nov;45:100937. doi: 10.1016/j.neo.2023.100937. Epub 2023 Sep 26. Neoplasia. 2023. PMID: 37769528 Free PMC article.
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Iachettini S, Terrenato I, Porru M, Di Vito S, Rizzo A, D'Angelo C, Petti E, Dinami R, Maresca C, Di Benedetto A, Palange A, Mulè A, Santoro A, Palazzo A, Fuso P, Stoppacciaro A, Vici P, Filomeno L, Di Lisa FS, Arcuri T, Krasniqi E, Fabi A, Biroccio A, Zizza P. Iachettini S, et al. Among authors: filomeno l. J Exp Clin Cancer Res. 2024 Mar 9;43(1):75. doi: 10.1186/s13046-024-02998-w. J Exp Clin Cancer Res. 2024. PMID: 38459559 Free PMC article.
HER2 mutation as an emerging target in advanced breast cancer.
Bon G, Di Lisa FS, Filomeno L, Arcuri T, Krasniqi E, Pizzuti L, Barba M, Messina B, Schiavoni G, Sanguineti G, Botti C, Cappelli S, Pelle F, Cavicchi F, Puccica I, Costantini M, Perracchio L, Maugeri-Saccà M, Ciliberto G, Vici P. Bon G, et al. Among authors: filomeno l. Cancer Sci. 2024 May 7. doi: 10.1111/cas.16148. Online ahead of print. Cancer Sci. 2024. PMID: 38715247 Review.
47 results